論文・技術情報追加のお知らせ

1. Risk of liver adverse events with nivolumab/ipilimumab combination therapy for hepatocellular carcinoma: A disproportionality analysis based on the Food and Drug Administration Adverse Event Reporting System data base.

肝細胞がんにおけるニボルマブ/イピリムマブ併用の肝障害解析。

対象DB：FAERS

2. Safety profile of herpes zoster vaccines in the United States: a descriptive and disproportionality analysis of adverse events reported to the vaccine adverse event reporting system (VAERS), 2017-2024.

帯状疱疹ワクチンのVAERSに基づく市販後安全性プロファイル解析。

対象DB：FAERS,VAERS

3. Nomogram-based prediction model for tocilizumab-induced leukopenia in adults using FAERS and PMDA data.

トシリズマブ誘発性白血球減少症予測ノモグラムモデルの開発。

対象DB：FAERS

4. A Disproportionality Analysis of beta-lactam Antibiotic Related Blood and Lymphatic System Disorders Based on the FDA Adverse Event Reporting System Database.

βラクタム系抗菌薬による血液・リンパ系障害の不均衡分析。

対象DB：FAERS

5. Real-world pharmacovigilance assessment of meropenem-associated adverse events: age stratification and time-to-onset analysis using FAERS.

メロペネム関連有害事象の年齢層別・発現時期不均衡分析。

対象DB：FAERS

6. Disproportionality analysis of methylphenidate-associated adverse events in pediatric patients using the FDA Adverse Event Reporting System: overall signals and stratification by gender and dosage form.

小児ADHD治療薬メチルフェニデートの副作用不均衡分析。

対象DB：FAERS

7. Neurological Adverse Events Associated With Immune Checkpoint Inhibitors Identified Through Disproportionality Analysis of the FDA Adverse Event Reporting System.

免疫チェックポイント阻害薬に伴う神経系副作用のFAERS解析。

対象DB：FAERS

8. Semaglutide Exposure During Pregnancy: Results from the FAERS Database.

妊娠中のセマグチド曝露に関するFAERS市販後安全性調査。

対象DB：FAERS

9. Adalimumab Safety in Inflammatory Bowel Disease: A Clinical Cohort Study with Time-to-Event Analysis and FAERS Signal Assessment.

炎症性腸疾患におけるアダリムマブの長期安全性コホート研究。

対象DB：FAERS

10. Empirical-Null Calibration Challenges Comparative CNS Safety Signals for Androgen-Receptor Pathway Inhibitors: A FAERS Re-Analysis.

前立腺がん治療薬（ARPI）の中枢神経系安全性不均衡分析。

対象DB：FAERS

11. Disproportionality Analysis of Breast Cancer-Related Reports Across Vitamin K Homologs in the FDA Adverse Event Reporting System.

ビタミンK同族体と乳がん報告に関するFAERS不均衡分析。

対象DB：FAERS

12. Possible Signals of Ocular Disorders Associated with Gabapentinoids: A Three-Arm Study.

ガバペンチノイド関連眼障害シグナルの多角的不均衡分析。

対象DB：FAERS

13. Real-World Patterns of Delayed Cutaneous Adverse Reactions to Antimicrobial Therapy in Children: A Case Series and FAERS Analysis Across Age Groups.

抗菌薬による遅発性皮膚悪性反応のリアルワールドパターン解析。

対象DB：FAERS

14. Infection-Related Adverse Events of Tisagenlecleucel in Pediatric Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia: A FAERS Pharmacovigilance Study.

小児難治性ALLにおけるティサゲンレクルーセル感染リスク。

対象DB：FAERS

15. Integration of FAERS database and network toxicology to investigate adverse drug events and potential toxicological mechanisms of triazole antifungal agents.

FAERSとネットワーク毒性学による薬剤副作用メカニズム解析。

対象DB：FAERS

16. Real-World Safety of Acoramidis in Transthyretin Amyloid Cardiomyopathy: A Pharmacovigilance Study.

トランスサイレチン型心アミロイドーシス薬の安全性評価。

対象DB：FAERS

17. Sex-Specific Safety Signals of Finerenone Versus Spironolactone: Insights From the FDA Adverse Event Reporting System.

フィネレノンとスピロノラクトンの性別副作用シグナル比較。

対象DB：FAERS

18. Comparative Analysis of Reported Adverse Events with Nirsevimab and Palivizumab in the FAERS Database.

乳幼児RSV予防薬ニルセビマブとパリビズマブの安全性比較。

対象DB：FAERS

19. Comparative Cardiovascular Pharmacovigilance of Semaglutide and Tirzepatide: A Food and Drug Administration Adverse Event Reporting System (FAERS) Database Analysis (2022-2026).

セマグチドとチルゼパチドの心血管安全性不均衡分析比較。

対象DB：FAERS

20. Disproportionality analysis of drug-induced myocarditis: Insights from the Food and Drug Administration Adverse Event Reporting System database.

FAERSを用いた薬剤誘発性心筋炎の不均衡分析調査。

対象DB：FAERS

21. Infection-related and Hepatobiliary Death Outcome Reports Involving Avacopan in the Japanese Pharmacovigilance Database.

アバコパン関連の感染症および肝胆道障害死に関する報告解析。

対象DB：JADER

22. Cutaneous lymphomas reported following the use of dupilumab, nemolizumab, tralokinumab, or lebrikizumab: A case investigation based on JADER database and disproportionality analysis.

デュピルマブ等の使用後に報告された皮膚リンパ腫に関する解析。

対象DB：JADER

23. Disproportionality analysis of opioid-related urinary retention using the JADER database: Focus on the lack of signal for transdermal fentanyl.

オピオイド関連尿閉のJADER不均衡分析と年齢層別評価。

対象DB：JADER

24. Global pharmacovigilance analysis of dermatologic toxicity in EGFR-TKI-treated NSCLC: a cross-database real-world study.

非小細胞肺がんにおけるEGFR-TKI皮膚毒性の不均衡分析。

対象DB：EudraVigilance

25. Metabolic and Inflammatory Adverse Drug Reactions Associated with Amlodipine: A Descriptive and Disproportionality Analysis of EudraVigilance Reports.

アムロジピン関連の代謝・炎症性副作用に関するFAERS解析。

対象DB：EudraVigilance

26. Metabolic Disturbances Associated with Beta-Blocker Therapy: New Insights from a Large-Scale Pharmacovigilance Study.

ベータ遮断薬に伴う代謝障害に関するFAERS不均衡分析。

対象DB：EudraVigilance

27. Drug-Associated Vanishing Bile Duct Syndrome: Screening for Potential Pharmaceutical Triggers Using the WHO Pharmacovigilance Database.

薬剤性消退性胆管症候群スクリーニングと原因薬特定。

対象DB：VigiBase

28. Real-world implementation, documentation, and prognostic implications of routinely recorded nutritional assessment based on the Global Leadership Initiative on Malnutrition criteria in critically ill patients: A nationwide retrospective cohort study.

肝疾患患者でのGLIM基準による低栄養診断の実態と予後解析。

対象DB：DPC

29. Effectiveness of Extended Intravenous Antibiotic Prophylaxis in Preventing Periprosthetic Joint Infection After Total Knee and Hip Arthroplasty: An Analysis of a Japanese Nationwide Database.

人工関節置換術後抗菌薬延長投与の感染予防効果コホート研究。

対象DB：DPC

30. Exploratory Clinical and Cost Evaluation of Robot-Assisted Adrenalectomy Using the hinotori Surgical Robotic System: A Single-Center Retrospective Study.

国産ロボットhinotoriによる副腎摘出術の費用効果評価。

対象DB：DPC

31. Nationwide epidemiology of hospitalized schistosomiasis in Japan: Coexistence of residual Schistosoma japonicum and non-japonicum infections.

日本における入院日本住血吸虫症の全国疫学と共存疾患の解析。

対象DB：DPC

32. Economic Burden and Treatment Patterns Among Patients Diagnosed With Vitiligo in Japan: An Observational Retrospective Cohort Study.

尋常性白斑患者における経済的負担と治療パターンの実態調査。

対象DB：JMDC

33. Ankle-brachial index and brachial-ankle pulse wave velocity as markers of severe aortic regurgitation: a hospital-based cohort study.

重症大動脈弁閉鎖不全症での足関節上腕血圧比等の有用性。

対象DB：MDV

34. Characterising patients with Alzheimer's disease in England: a cohort study using data from Clinical Practice Research Datalink linked to Hospital Episode Statistics.

英国のアルツハイマー病患者における併存疾患と医療利用の実態。

対象DB：CPRD

35. Blood-test monitoring strategies for patients established on immune-suppressing drugs: a mixed-methods study.

免疫抑制薬長期投与患者での血液検査モニタリングの評価。

対象DB：CPRD

36. Personalized evaluation of NT-proBNP and clinical characteristics in suspected heart failure: the PRECISE-HF study.

心不全疑い患者でのNT-proBNPによる個別化リスク評価。

対象DB：CPRD

37. Increasing Trends in Hospitalisation With Diabetic Ketoacidosis at Type 1 Diabetes Diagnosis Among Children and Youth in the United States and England, 2002-2020.

小児・若年者の1型糖尿病発症時ケトアシドーシス入院傾向調査。

対象DB：CPRD

38. Antidepressant Prescribing Trends for Adults With and Without Autism in the United Kingdom From 1997 to 2023: A Population-Based Cohort Study Using Clinical Practice Research Datalink Aurum.

英国自閉症成人における抗うつ薬処方動向の経時的調査。

対象DB：CPRD

39. Frequency and prognostic outcomes of emergency diagnosis in 13 non-neoplastic conditions in England: A population-based cohort study using linked electronic health records of 1.7 million patients.

非がん性疾患13種における緊急診断の頻度と予後影響の調査。

対象DB：CPRD

40. Sex differences in trajectories to cardio-renal and mental health outcomes following the onset of type 2 diabetes: An observational cohort study using multi-state analysis in the UK Clinical Practice Research Datalink.

2型糖尿病診断後の心腎・精神疾患転帰における性別差異解析。

対象DB：CPRD